ArticleNPJ biofilms and microbiomes2017
Human microbiome signatures of differential colorectal cancer drug metabolism.
Article in NPJ biofilms and microbiomes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 148 citations in OpenAlex.
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism.npj biomedical innovations · 2026Review
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Personalizing Nutritional Therapy in Pediatric Oncology: The Role of Gut Microbiome Profiling and Metabolomics in Mitigating Mucositis and Enhancing Immune Response to Chemotherapy.Children (Basel, Switzerland) · 2026Review
- A generalized supervised contrastive learning framework for integrative multi-omics prediction models.Frontiers in microbiomes · 2026Article
- Microbiome dysbiosis and its modulation in cancer development, prevention and therapy.Frontiers in oncology · 2026Review
- Integrative oncology in colorectal cancer: evidence-based strategies from prevention through survivorship.Frontiers in oncology · 2026Review
- HAFMMDA: HIN2vec-Based Attentional Factorization Machines for Predicting Microbe-Drug Associations.Interdisciplinary sciences, computational life sciences · 2025Article
- Characterization of fecal deglucuronidation activity in healthy subjects and in patients treated with fecal microbiota transplantation.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025Review
- Metagenomic Profiling of Gut Microbiota in Kidney Precision Medicine Project Participants With CKD and AKI.Comprehensive physiology · 2025Article
- Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment.Discover oncology · 2025Review
- Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice.NPJ biofilms and microbiomes · 2025Article
- Gut microbiome in colorectal cancer: metagenomics from bench to bedside.JNCI cancer spectrum · 2025Review
- Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases.Biomedicines · 2025Review
- Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response.Cancer communications (London, England) · 2024Review
- Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method.Pharmaceutical research · 2024Article
- Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?Frontiers in immunology · 2024Review
- MKAN-MMI: empowering traditional medicine-microbe interaction prediction with masked graph autoencoders and KANs.Frontiers in pharmacology · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
It is well appreciated that microbial metabolism of drugs can influence treatment efficacy. Microbial β-glucuronidases in the gut can reactivate the excreted, inactive metabolite of irinotecan, a first-line chemotherapeutic for metastatic colorectal cancer. Reactivation causes adverse drug responses, including severe diarrhea. However, a direct connection between irinotecan metabolism and the composition of an individual's gut microbiota has not previously been made. Here, we report quantitative evidence of inter-individual variability in microbiome metabolism of the inactive metabolite of irinotecan to its active form. We identify a high turnover microbiota metabotype with potentially elevated risk for irinotecan-dependent adverse drug responses. We link the high turnover metabotype to unreported microbial β-glucuronidases; inhibiting these enzymes may decrease irinotecan-dependent adverse drug responses in targeted subsets of patients. In total, this study reveals metagenomic mining of the microbiome, combined with metabolomics, as a non-invasive approach to develop biomarkers for colorectal cancer treatment outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.